Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(7):951–959. doi: 10.1038/bjc.1997.166

Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines.

P S Stonelake 1, C E Jones 1, J P Neoptolemos 1, P R Baker 1
PMCID: PMC2222759  PMID: 9083329

Abstract

The relative importance of different proteinases, and their inhibition, in the breakdown of human endothelial basement membrane (BM) by MDA-MB-231 and MCF7ADR human breast cancer cell lines has been studied using 35S-labelled BM-coated 96-well culture plates. Basement membrane degradation (BMD) was independent of cell proliferation above the seeding density. Inhibitors of aspartic (pepstatin and PD 134678-0073) and cysteine proteinases (E64) had little effect on BMD under normal culture conditions, suggesting that cathepsins D, B and L have only a minor role. In contrast, inhibitors of urokinase-type plasminogen activator (uPA) and/or plasminogen activation to plasmin (aprotinin, amiloride, EACA, tranexamic acid, anti-uPA antibody) all reduced BMD by MDA-MB-231 cells by approximately 30-40%, but only in the presence of serum or plasminogen. BB94, an inhibitor of matrix metalloproteinases (MMPs), also reduced BMD by about 30% under these conditions but was similarly effective in serum-free medium. Combinations of BB94 with any of the uPA/plasminogen activation inhibitors in serum-containing medium had additive effects, while BB94 with pepstatin and E64 under serum-free conditions reduced BMD to 16% of control. Serum-containing conditioned medium exhibited appreciable BMD, largely due to aprotinin-inhibitable activity. Although small reductions in cell proliferation were seen with some inhibitors, the combination of BB94 with E64 or E64d reduced the cell population by about 60% under serum-containing conditions. These in vitro observations suggest that combinations of proteinase inhibitors, particularly of uPA/plasminogen activation and MMPs, may merit clinical evaluation as potential antimetastatic therapy for breast cancer.

Full text

PDF
951

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALKJAERSIG N., FLETCHER A. P., SHERRY S. xi-Aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem. 1959 Apr;234(4):832–837. [PubMed] [Google Scholar]
  2. Azzam H. S., Arand G., Lippman M. E., Thompson E. W. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst. 1993 Nov 3;85(21):1758–1764. doi: 10.1093/jnci/85.21.1758. [DOI] [PubMed] [Google Scholar]
  3. Barrett A. J., Kembhavi A. A., Brown M. A., Kirschke H., Knight C. G., Tamai M., Hanada K. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J. 1982 Jan 1;201(1):189–198. doi: 10.1042/bj2010189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boike G., Lah T., Sloane B. F., Rozhin J., Honn K., Guirguis R., Stracke M. L., Liotta L. A., Schiffmann E. A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells. Melanoma Res. 1992 Jan-Feb;1(5-6):333–340. doi: 10.1097/00008390-199201000-00004. [DOI] [PubMed] [Google Scholar]
  5. Briozzo P., Morisset M., Capony F., Rougeot C., Rochefort H. In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. Cancer Res. 1988 Jul 1;48(13):3688–3692. [PubMed] [Google Scholar]
  6. Brünner N., Boysen B., Rømer J., Spang-Thomsen M. The nude mouse as an in vivo model for human breast cancer invasion and metastasis. Breast Cancer Res Treat. 1993;24(3):257–264. doi: 10.1007/BF01833265. [DOI] [PubMed] [Google Scholar]
  7. Buck M. R., Karustis D. G., Day N. A., Honn K. V., Sloane B. F. Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J. 1992 Feb 15;282(Pt 1):273–278. doi: 10.1042/bj2820273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Davies B., Brown P. D., East N., Crimmin M. J., Balkwill F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 1993 May 1;53(9):2087–2091. [PubMed] [Google Scholar]
  9. Davies B., Miles D. W., Happerfield L. C., Naylor M. S., Bobrow L. G., Rubens R. D., Balkwill F. R. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer. 1993 May;67(5):1126–1131. doi: 10.1038/bjc.1993.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. DeClerck Y. A., Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer. 1994;30A(14):2170–2180. doi: 10.1016/0959-8049(94)00460-m. [DOI] [PubMed] [Google Scholar]
  11. Doherty A. M., Sircar I., Kornberg B. E., Quin J., 3rd, Winters R. T., Kaltenbronn J. S., Taylor M. D., Batley B. L., Rapundalo S. R., Ryan M. J. Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors. J Med Chem. 1992 Jan;35(1):2–14. doi: 10.1021/jm00079a001. [DOI] [PubMed] [Google Scholar]
  12. Fidler I. J. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1990 Oct 1;50(19):6130–6138. [PubMed] [Google Scholar]
  13. Fritz H., Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 1983;33(4):479–494. [PubMed] [Google Scholar]
  14. Gabrijelcic D., Svetic B., Spaić D., Skrk J., Budihna M., Dolenc I., Popovic T., Cotic V., Turk V. Cathepsins B, H and L in human breast carcinoma. Eur J Clin Chem Clin Biochem. 1992 Feb;30(2):69–74. [PubMed] [Google Scholar]
  15. Garcia M., Derocq D., Pujol P., Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene. 1990 Dec;5(12):1809–1814. [PubMed] [Google Scholar]
  16. Hayakawa T., Yamashita K., Ohuchi E., Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci. 1994 Sep;107(Pt 9):2373–2379. doi: 10.1242/jcs.107.9.2373. [DOI] [PubMed] [Google Scholar]
  17. Holst-Hansen C., Johannessen B., Høyer-Hansen G., Rømer J., Ellis V., Brünner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis. 1996 May;14(3):297–307. doi: 10.1007/BF00053903. [DOI] [PubMed] [Google Scholar]
  18. Johnson M. D., Torri J. A., Lippman M. E., Dickson R. B. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res. 1993 Feb 15;53(4):873–877. [PubMed] [Google Scholar]
  19. Kellen J. A., Mirakian A., Kolin A. Antimetastatic effect of amiloride in an animal tumour model. Anticancer Res. 1988 Nov-Dec;8(6):1373–1376. [PubMed] [Google Scholar]
  20. Kikuchi Y., Kizawa I., Oomori K., Matsuda M., Kato K. Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amount of ascites. Acta Obstet Gynecol Scand. 1986;65(5):453–456. doi: 10.3109/00016348609157383. [DOI] [PubMed] [Google Scholar]
  21. Kikuchi Y., Kizawa I., Oomori K., Miyauchi M., Kita T., Sugita M., Tenjin Y., Kato K. Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. Cancer Res. 1987 Jan 15;47(2):592–596. [PubMed] [Google Scholar]
  22. Kobayashi H., Ohi H., Sugimura M., Shinohara H., Fujii T., Terao T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res. 1992 Jul 1;52(13):3610–3614. [PubMed] [Google Scholar]
  23. Lim Y. T., Sugiura Y., Laug W. E., Sun B., Garcia A., DeClerck Y. A. Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. J Cell Physiol. 1996 May;167(2):333–340. doi: 10.1002/(SICI)1097-4652(199605)167:2<333::AID-JCP18>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  24. Mangel W. F., Toledo D. L., Nardulli A. M., Reiner G. C., Norman M. J., Katzenellenbogen B. S. Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. J Steroid Biochem. 1988;30(1-6):79–88. doi: 10.1016/0022-4731(88)90079-9. [DOI] [PubMed] [Google Scholar]
  25. Mignatti P., Robbins E., Rifkin D. B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 1986 Nov 21;47(4):487–498. doi: 10.1016/0092-8674(86)90613-6. [DOI] [PubMed] [Google Scholar]
  26. Miles L. A., Plow E. F. Binding and activation of plasminogen on the platelet surface. J Biol Chem. 1985 Apr 10;260(7):4303–4311. [PubMed] [Google Scholar]
  27. Minafra S., Morello V., Glorioso F., La Fiura A. M., Tomasino R. M., Feo S., McIntosh D., Woolley D. E. A new cell line (8701-BC) from primary ductal infiltrating carcinoma of human breast. Br J Cancer. 1989 Aug;60(2):185–192. doi: 10.1038/bjc.1989.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Montcourrier P., Mangeat P. H., Salazar G., Morisset M., Sahuquet A., Rochefort H. Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. Cancer Res. 1990 Sep 15;50(18):6045–6054. [PubMed] [Google Scholar]
  29. Monteagudo C., Merino M. J., San-Juan J., Liotta L. A., Stetler-Stevenson W. G. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol. 1990 Mar;136(3):585–592. [PMC free article] [PubMed] [Google Scholar]
  30. Morris V. L., Tuck A. B., Wilson S. M., Percy D., Chambers A. F. Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Clin Exp Metastasis. 1993 Jan;11(1):103–112. doi: 10.1007/BF00880071. [DOI] [PubMed] [Google Scholar]
  31. Nemeth J. A., Rafe A., Steiner M., Goolsby C. L. TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp Cell Res. 1996 Apr 10;224(1):110–115. doi: 10.1006/excr.1996.0117. [DOI] [PubMed] [Google Scholar]
  32. Reich R., Thompson E. W., Iwamoto Y., Martin G. R., Deason J. R., Fuller G. C., Miskin R. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res. 1988 Jun 15;48(12):3307–3312. [PubMed] [Google Scholar]
  33. Rozhin J., Gomez A. P., Ziegler G. H., Nelson K. K., Chang Y. S., Fong D., Onoda J. M., Honn K. V., Sloane B. F. Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors. Cancer Res. 1990 Oct 1;50(19):6278–6284. [PubMed] [Google Scholar]
  34. Rozhin J., Sameni M., Ziegler G., Sloane B. F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994 Dec 15;54(24):6517–6525. [PubMed] [Google Scholar]
  35. Scragg M. A., Ferreira L. R. Evaluation of different staining procedures for the quantification of fibroblasts cultured in 96-well plates. Anal Biochem. 1991 Oct;198(1):80–85. doi: 10.1016/0003-2697(91)90509-r. [DOI] [PubMed] [Google Scholar]
  36. Shoji-Kasai Y., Senshu M., Iwashita S., Imahori K. Thiol protease-specific inhibitor E-64 arrests human epidermoid carcinoma A431 cells at mitotic metaphase. Proc Natl Acad Sci U S A. 1988 Jan;85(1):146–150. doi: 10.1073/pnas.85.1.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sledge G. W., Jr, Qulali M., Goulet R., Bone E. A., Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst. 1995 Oct 18;87(20):1546–1550. doi: 10.1093/jnci/87.20.1546. [DOI] [PubMed] [Google Scholar]
  38. Stephens R. W., Pöllänen J., Tapiovaara H., Leung K. C., Sim P. S., Salonen E. M., Rønne E., Behrendt N., Danø K., Vaheri A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol. 1989 May;108(5):1987–1995. doi: 10.1083/jcb.108.5.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Thompson E. W., Paik S., Brünner N., Sommers C. L., Zugmaier G., Clarke R., Shima T. B., Torri J., Donahue S., Lippman M. E. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol. 1992 Mar;150(3):534–544. doi: 10.1002/jcp.1041500314. [DOI] [PubMed] [Google Scholar]
  40. Towle M. J., Lee A., Maduakor E. C., Schwartz C. E., Bridges A. J., Littlefield B. A. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res. 1993 Jun 1;53(11):2553–2559. [PubMed] [Google Scholar]
  41. Uetsuji S., Yamamura M., Takai S., Hioki K., Yamamoto M. Effect of aprotinin on metastasis of Lewis lung tumor in mice. Surg Today. 1992;22(5):439–442. doi: 10.1007/BF00308795. [DOI] [PubMed] [Google Scholar]
  42. Vasishta A., Baker P. R., Preece P. E., Wood R. A., Cuschieri A. Inhibition of proteinase-like peptidase activities in serum and tissue from breast cancer patients. Anticancer Res. 1988 Jul-Aug;8(4):785–789. [PubMed] [Google Scholar]
  43. Vassalli J. D., Belin D. Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 1987 Apr 6;214(1):187–191. doi: 10.1016/0014-5793(87)80039-x. [DOI] [PubMed] [Google Scholar]
  44. Yagel S., Warner A. H., Nellans H. N., Lala P. K., Waghorne C., Denhardt D. T. Suppression by cathepsin L inhibitors of the invasion of amnion membranes by murine cancer cells. Cancer Res. 1989 Jul 1;49(13):3553–3557. [PubMed] [Google Scholar]
  45. Yee C., Shiu R. P. Degradation of endothelial basement membrane by human breast cancer cell lines. Cancer Res. 1986 Apr;46(4 Pt 1):1835–1839. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES